Presence of Gal‐α1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Xenotransplantation

• Publication date

  2003-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1034/j.1399-3089.2003.00110.xPMID 12694540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frameshift and Nonsense Mutations in a Human Genomic Sequence Homologous to a Murine UDP-Gal:&D-Gal( 1,4)-D-GlcNAc CY( 1,3)-Galactosyltransferase cDNA*

  2001cited by this paper
• Discordant neural tissue xenografts survive longer in immunoglobulin deficient mice.

  1999cited by this paper
• Complement and anti-α-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum

  1999cited by this paper
• Human serum-resistant retroviral vector particles from galactosyl (α1–3) galactosyl containing nonprimate cell lines

  1999cited by this paper
• The rejection of neural xenotransplants: a role for antibodies.

  1999cited by this paper
• Quantitation and characterization of anti‐Galα1–3Gal antibodies in sera of 200 healthy persons

  1999cited by this paper
• Medical and Educational Fields in Logopedics in The Netherlands:A Comparison in Historical and European Perspective

  1998cited by this paper
• Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts

  1998cited by this paper
• Delayed Xenograft Rejection

  1997cited by this paper
• Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope.

  1997cited by this paper
• Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients

  1996cited by this paper
• Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response

  1996cited by this paper
• トランスジェニックマウスおよびトランスジェニックブタにおけるα(1,2)フコシルトランスフェラーゼの発現によるGal(α1,3)Galのレベルの低下

  1996cited by this paper
• Development of Amphotropic Murine Retrovirus Vectors Resistant to Inactivation by Human Serum

  1996cited by this paper
• Delayed xenograft rejection.

  1996cited by this paper
• Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience.

  1996cited by this paper
• Transplantation of discordant xenografts: a challenge revisited.

  1996cited by this paper
• Extracorporeal (“ex vivo”) connection of pig kidneys to humans. II. The anti‐pig antibody response

  1996cited by this paper
• Immunoisolated Xenogeneic Chromaffin Cell Therapy for Chronic Pain: Initial Clinical Experience

  1996cited by this paper
• Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C2C12 Myoblasts

  1996cited by this paper
• Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Using a Polymer Encapsulated Xenogenic Cell Line Engineered to Secrete hCNTF. Lausanne University Medical School, Lausanne, Switzerland

  1996cited by this paper
• Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase.

  1996cited by this paper
• Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells.

  1996cited by this paper
• Functional Impairment Of Enteric Smooth Muscle And Nerves Caused By Chronic Intestinal Allograft Rejection Regresses After Fk506 Rescue

  1995cited by this paper
• ENZYMATIC REMOVAL OF ALPHA‐GALACTOSYL EPITOPES FROM PORCINE ENDOTHELIAL CELLS DIMINISHES THE CYTOTOXIC EFFECT OF NATURAL ANTIBODIES

  1995cited by this paper
• Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts.

  1995cited by this paper
• High-titer packaging cells producing recombinant retroviruses resistant to human serum

  1995cited by this paper
• THE HUMORAL IMMUNE RESPONSE IN HUMANS FOLLOWING CROSS‐PERFUSION OF PORCINE ORGANS

  1995cited by this paper
• Xenoreactive natural antibodies in the world of natural antibodies: typical or unique?

  1995cited by this paper
• Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis

  1995cited by this paper
• Removal Of Baboon And Human Antiporcine Igg And Igm Natural Antibodies By Immunoadsorption: Results of In Vitro And In Vivo Studies

  1995cited by this paper
• The Effects of Human Serum and Cerebrospinal Fluid on Retroviral Vectors and Packaging Cell Lines

  1995cited by this paper
• Transplantation of porcine fetal pancreas to diabetic patients.

  1995cited by this paper
• Anti‐Gal activity In diabetic patients transplanted with fetal porcine Islet cell clusters

  1995cited by this paper
• Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell

  1994cited by this paper
• Galα(1,3)Gal, the Major Xenoantigen(s) Recognised in Pigs by Human Natural Antibodies

  1994cited by this paper
• Porcine platelet antigens recognized by human xenoreactive natural antibodies.

  1994cited by this paper
• Transplantation of porcine fetal pancreas to diabetic patients.

  1994cited by this paper
• Variation in expression of porcine xenogeneic antigens.

  1994cited by this paper
• Specificities of human IgM and IgG anticarbohydrate xenoantibodies found in the sera of diabetic patients grafted with fetal pig islets

  1994cited by this paper
• TRANSPLANTATION IN HUMANS OF ENCAPSULATED XENOGENEIC CELLS WITHOUT IMMUNOSUPPRESSION: A PRELIMINARY REPORT

  1994cited by this paper
• Gamma-interferon gene expression in human renal allograft fine-needle aspirates.

  1994cited by this paper
• Oligosaccharides and Discordant Xenotransplantation

  1994cited by this paper
• Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans.

  1993cited by this paper
• Specific intravenous carbohydrate therapy: a new approach to the inhibition of antibody-mediated rejection following ABO-incompatible allografting and discordant xenografting.

  1993cited by this paper
• Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique.

  1991cited by this paper
• Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys.

  1991cited by this paper
• Immunopathology of hyperacute xenograft rejection in a swine-to-primate model.

  1991cited by this paper
• Molecular cloning, sequence, and expression of a human GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase cDNA that can form the H blood group antigen.

  1990cited by this paper
• Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA.

  1990cited by this paper
• Bovine alpha 1----3-galactosyltransferase: isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA.

  1989cited by this paper
• The determination of the complement components C1q, C4 and C3 in serum and cerebrospinal fluid by radioimmunoassay.

  1985cited by this paper
• Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis.

  1984cited by this paper
• An alpha-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds. Isolation by affinity chromatography and characterization.

  1974cited by this paper
• Purification and characterization of an anti-H(O) phytohemagglutinin of Ulex europeus.

  1969cited by this paper
• RESPIRATION AND THE CEREBROSPINAL FLUID.

  1964cited by this paper
• Molecular cloning, sequence, and expression of a human GDP-L-fucose:,8-D-galactoside 2-a-L-fucosyltransferase cDNA that can form the H blood group antigen

  year unknowncited by this paper

• Glyco-engineered HEK 293-F cell lines for the production of therapeutic glycoproteins with human N-glycosylation and improved pharmacokinetics.

  2021cites this paper
• N-Glycosylation of IgG and IgG-Like Recombinant Therapeutic Proteins: Why Is It Important and How Can We Control It?

  2020cites this paper
• To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.

  2017cites this paper
• Effect of Incubation of PK-15 Line Cells with Cryoprotectants on Amount of Gal-alpha-1,3-Gal Epitopes

  2016cites this paper
• VU Research Portal Methods for the glycosylation analysis of therapeutic antibodies

  2015cites this paper
• VU Research Portal Methods for the glycosylation analysis of therapeutic antibodies

  2015cites this paper
• Fc glycans of therapeutic antibodies as critical quality attributes

  2015cites this paper
• High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples.

  2013cites this paper
• N-glycanes containing galactose-alpha-1,3-galactose in glycoprotein products produced from cho cells

  2009cites this paper
• Apolipoprotein E delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice.

  2005cites this paper
• Targeting the Brain: Focal Delivery of Natural Anticonvulsant Molecules

  2005cites this paper
• Apolipoprotein E ( apoE ) delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice

  2005cites this paper